Vicapsys Life Sciences, Inc.
VICP · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.86 | -10.30 | -2.75 | 1.74 |
| FCF Yield | 0.00% | 0.00% | 0.24% | 0.13% |
| EV / EBITDA | -364.83 | -249.99 | -304.55 | -331.56 |
| Quality | ||||
| ROIC | 6.97% | 9.93% | 9.62% | 9.17% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.77 | 1.01 | 0.03 | 0.14 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 85.00% | 936.32% |
| Safety | ||||
| Net Debt / EBITDA | -3.31 | -2.48 | -2.46 | -2.54 |
| Interest Coverage | -20.99 | -27.74 | -5.43 | -22.04 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |